verapamil has been researched along with Dyslipidemia in 2 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Verapamil treatment reduced the severity and number of lytic lesions in cardiomyocytes, induced considerable glycogen accumulation in the sarcoplasm and its sequestration, promoted normalization, and prevented pronounced decrease of the relative RyR2 mRNA and SERCA2a mRNA in rat myocardium." | 5.42 | Expression of ryanodine receptor mRNA and sarcoplasmic Ca²⁺-ATPase mRNA in the myocardium and intracellular reorganization of cardiomyocytes in dyslipidemia and during verapamil treatment. ( Klinnikova, MG; Lushnikova, EL; Nepomnyashchikh, LM; Pichigin, VI; Yuzhik, EI, 2015) |
| "Verapamil treatment reduced the severity and number of lytic lesions in cardiomyocytes, induced considerable glycogen accumulation in the sarcoplasm and its sequestration, promoted normalization, and prevented pronounced decrease of the relative RyR2 mRNA and SERCA2a mRNA in rat myocardium." | 1.42 | Expression of ryanodine receptor mRNA and sarcoplasmic Ca²⁺-ATPase mRNA in the myocardium and intracellular reorganization of cardiomyocytes in dyslipidemia and during verapamil treatment. ( Klinnikova, MG; Lushnikova, EL; Nepomnyashchikh, LM; Pichigin, VI; Yuzhik, EI, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yuzhik, EI | 1 |
| Lushnikova, EL | 1 |
| Klinnikova, MG | 1 |
| Pichigin, VI | 1 |
| Nepomnyashchikh, LM | 1 |
| Halna du Fretay, X | 1 |
| Blanchard-Lemoine, B | 1 |
| Schnebert, B | 1 |
| Viossat, J | 1 |
2 other studies available for verapamil and Dyslipidemia
| Article | Year |
|---|---|
Expression of ryanodine receptor mRNA and sarcoplasmic Ca²⁺-ATPase mRNA in the myocardium and intracellular reorganization of cardiomyocytes in dyslipidemia and during verapamil treatment.
Topics: Animals; Diet, Atherogenic; DNA Primers; Dyslipidemias; Male; Myocardium; Myocytes, Cardiac; Rats; R | 2015 |
[Variant angina: what to think in 2011?].
Topics: Adrenergic beta-Antagonists; Angina Pectoris, Variant; Coronary Angiography; Diagnosis, Differential | 2011 |